CINECA IRIS Institutional Research Information System

TRUNFIO, MATTIA GIOVANNI CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.798
EU - Europa 956
AS - Asia 559
SA - Sud America 132
AF - Africa 76
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.545
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.756
IT - Italia 353
IE - Irlanda 167
CN - Cina 156
SG - Singapore 103
SE - Svezia 98
VN - Vietnam 64
IN - India 56
AT - Austria 53
DE - Germania 52
GB - Regno Unito 47
FR - Francia 42
CO - Colombia 40
BR - Brasile 36
ES - Italia 28
HK - Hong Kong 24
AR - Argentina 23
TH - Thailandia 23
AU - Australia 22
CA - Canada 19
ID - Indonesia 19
IR - Iran 19
ZA - Sudafrica 19
JP - Giappone 17
MX - Messico 17
NL - Olanda 17
FI - Finlandia 16
PE - Perù 15
KR - Corea 13
MY - Malesia 13
KE - Kenya 12
PH - Filippine 12
TW - Taiwan 12
UA - Ucraina 12
RU - Federazione Russa 10
GR - Grecia 9
CL - Cile 8
CZ - Repubblica Ceca 8
NG - Nigeria 8
TZ - Tanzania 8
PY - Paraguay 7
PL - Polonia 6
PT - Portogallo 6
SA - Arabia Saudita 6
TR - Turchia 6
BE - Belgio 5
CH - Svizzera 5
DZ - Algeria 5
IL - Israele 5
HU - Ungheria 4
MW - Malawi 4
PK - Pakistan 4
UG - Uganda 4
CR - Costa Rica 3
DK - Danimarca 3
EG - Egitto 3
NO - Norvegia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CD - Congo 2
GH - Ghana 2
HN - Honduras 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NA - Namibia 2
RE - Reunion 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EC - Ecuador 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GT - Guatemala 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
SD - Sudan 1
UY - Uruguay 1
YE - Yemen 1
ZW - Zimbabwe 1
Totale 3.545
Salva come PNG Salva come JPEG
Città #
Chandler 374
Dublin 167
Fairfield 113
Ashburn 92
Torino 82
Redwood City 80
Turin 75
Nyköping 67
Singapore 66
Medford 61
Beijing 50
Wilmington 50
Woodbridge 50
Princeton 45
Cambridge 38
Houston 35
Ann Arbor 33
Jacksonville 29
San Diego 29
Seattle 27
Milan 25
Hangzhou 22
New York 21
Hebei 19
Dong Ket 16
Dearborn 13
Seoul 13
Washington 13
Lima 11
Vienna 11
Buenos Aires 10
Hong Kong 10
London 10
Medellín 10
Melbourne 10
Grugliasco 9
Ho Chi Minh City 9
Mumbai 9
Paris 9
São Paulo 9
Upper Marlboro 9
Bangkok 8
Helsinki 8
Pisa 8
Villeurbanne 8
Barcelona 7
Barranquilla 7
Chengdu 7
Duncan 7
Falls Church 7
Frankfurt am Main 7
Guiyang 7
Jakarta 7
Johannesburg 7
Kuala Lumpur 7
Los Angeles 7
Norwalk 7
Raleigh 7
Riverton 7
Santiago 7
Yekaterinburg 7
Abuja 6
Brno 6
Cartagena 6
Central 6
Chandigarh 6
Fredericton 6
Genoa 6
Hefei 6
Lappeenranta 6
Ottawa 6
Algiers 5
Chicago 5
Guangzhou 5
Gurgaon 5
Istanbul 5
Jinan 5
Nanterre 5
Pune 5
Richmond 5
Sydney 5
Tainan City 5
Bengaluru 4
Boston 4
Brussels 4
Buffalo 4
Cape Town 4
Central District 4
Chapel Hill 4
Cinisello Balsamo 4
Collegno 4
Dar es Salaam 4
Dodoma 4
La Plata 4
Londrina 4
Minneapolis 4
Modena 4
Monza 4
Nanjing 4
Rio de Janeiro 4
Totale 2.162
Salva come PNG Salva come JPEG
Nome #
Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern 353
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 249
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 215
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 149
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 129
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders: Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients 127
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series 125
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 120
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy 117
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? 108
Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections 105
Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study 93
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection 69
Co-infection with other respiratory pathogens in COVID-19 patients 68
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity 67
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 66
Ultrasonography of an oral cavity onchocercidae nodule 62
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients 61
Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders 61
The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes 57
Blood–brain barrier impairment in patients living with hiv: Predictors and associated biomarkers 56
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 51
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases 50
Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient 50
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 49
The manifesto of pharmacoenosis: Merging hiv pharmacology into pathocoenosis and syndemics in developing countries 48
Alzheimer Dementia in People Living With HIV 47
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases 46
HIV-1 detection in the olfactory mucosa of HIV-1 infected participants 45
JC virus DNA in cerebrospinal fluid: insight into clinical significance 43
Clinical and VIRO-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients 42
Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: A parallel cohort study in healthcare workers 41
Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis 40
Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review 40
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 36
Screening Accuracy of Mini Addenbrooke’s Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV 34
Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy 33
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs 32
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 31
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition 31
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV 29
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases 27
Malignant melanoma in people living with HIV/AIDS: Can we know more, can we do better? 27
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 25
Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART) 23
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 22
COVID-19: A Possible Contribution of the MAPK Pathway 21
What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? 21
Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants 21
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 20
Concurrent and Subsequent Co-Infections of Clostridioides difficile Colitis in the Era of Gut Microbiota and Expanding Treatment Options 19
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia 19
The role of antirheumatics in patients with COVID-19 19
Norepinephrine may improve survival of septic shock patients in a low-resource setting: a proof-of-concept study on feasibility and efficacy outside the Intensive Care Unit 18
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata 15
Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV 13
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review 10
Beyond the Syndemic of Opioid Use Disorders and HIV: The Impact of Opioids on Viral Reservoirs 8
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV 8
Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV 7
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen 7
Use of different anticholinergic scales and their correlation with anticholinergic symptom burden in a cohort of people living with HIV 6
Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV 5
Living with HIV and Getting Vaccinated: A Narrative Review 4
Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV 4
Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV 3
Use of self-prescribed medications and complementary medicines in a cohort of women with HIV 3
Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA 3
Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV 3
Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and Omicron era: A real‐life cohort study 3
Cognitive criteria in HIV: greater consensus is needed 3
Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis 3
Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 3
Association between tight junction proteins and cognitive performance in untreated persons with HIV 2
Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV 2
The presence of resistance-associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV-1 escape: A multicentric retrospective analysis 2
Totale 3.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.852
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.852
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020225 2 2 3 19 7 19 24 21 25 23 30 50
2020/2021419 20 22 37 18 39 22 32 12 16 67 50 84
2021/2022787 58 50 35 42 61 70 42 51 22 77 121 158
2022/20231.200 93 123 51 123 98 268 73 95 97 39 81 59
2023/2024868 94 113 47 47 63 116 57 56 22 76 54 123
2024/202535 35 0 0 0 0 0 0 0 0 0 0 0
Totale 3.674